Minimal change disease (MCD) is the most common nephrotic syndrome in childhood, yet its cause is unknown. While steroids initially induce remission in most patients, nearly all children suffer multiple relapses. Complications also may occur, such as AKI, infection, blood clots and progression to kidney failure. Without a molecular understanding of the mechanisms leading to podocyte injury in MCD, we will be unable to develop targeted therapies or biomarkers for these children. Gabriel Cara-Fuentes, MD, aims to help identify the cause, find biomarkers that can predict clinical outcomes and develop specific, targeted therapies to mitigate this devastating disease.